News Releases

Below are the latest News Releases for Clearmind Medicine Inc.

16

August

2024

Clearmind Medicine and Yissum Expand Collaboration with International Patent Application for Generation 3.0 Psychedelic Compounds
Read More
6

August

2024

Clearmind Medicine: New Scientific Publication Shows MEAI's Potential as a Novel Weight Loss Drug
Read More
31

July

2024

Clearmind Medicine Concludes the Successful Participation in the Psychedelic Medicine – Israel 2024 Conference
Read More
19

July

2024

Clearmind Medicine Signs an Agreement to Source Manufacturers and Distributors for its Alcohol Substitute Beverage Product
Read More
16

July

2024

Clearmind Obtains IND Approval from the FDA to Start Phase I/IIa Clinical Trial with its Innovative Treatment for Alcoholism
Read More
16

July

2024

Clearmind Medicine Announces Submission of US Patent Application for Treating Metabolic Syndrome and Weight-loss
Read More
12

July

2024

Clearmind Medicine to Present Groundbreaking Research at Psychedelic Medicine – Israel 2024 Conference
Read More
28

June

2024

Clearmind Medicine Granted Patent Approval in Hong Kong for its Binge Behaviors Treatment
Read More
11

June

2024

Clearmind Medicine Revolutionizes the $13 Billion NonAlcoholic Beverages Market with its Psychedelic-Based Drink
Read More
10

May

2024

Clearmind Medicine Advances its Proprietary Psychedelic- Based Synthetic Alcohol Beverage Product
Read More
7

May

2024

Clearmind Medicine Secures Exclusive Global Rights to Breakthrough Psychedelic Compounds for PTSD Treatment
Read More
30

April

2024

Clearmind Applies to Cease Being a Reporting Issuer in Canada
Read More
17

April

2024

Clearmind Announces Exclusive Licensing Agreement for Generation 3.0 Psychedelic Compounds for the Treatment of Mental Disorders
Read More
10

April

2024

Clearmind Medicine Files U.S. Patent Application for Psychedelic-Based Treatment for Eating Disorders
Read More
9

April

2024

Clearmind Medicine CEO Issues Letter to Shareholders
Read More